Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant monoclonal antibody to IL17A. Secukinumab is a human monoclonal antibody designed for the treatments of uveitis, rheumatoid arthritis, and psoriasis. It targets member A from the cytokine family of interleukin 17.
IgG1 - kappa
HuIL-17 coupled 10 KLH mixed 1:1 with huIL-17 in Gerbu adjuvant.
Suitable for use in IF, IP, Neut, FuncS, ELISA, FC, ICC and most other immunological methods.
Tested positive against native human antigen.
Immunoglobulin G1, anti-(human interleukin-17A (IL-17, cytotoxic T-lymphocyte-associated antigen 8)); human monoclonal AIN457 γ1 heavy chain (230-215")-disulfide with human monoclonal AIN457 kappa light chain dimer
Predicted N terminal
H Chain: EVQLVES; L Chain: EIVLTQS
>95.0% as determined by Analysis by RP-HPLC & analysis by SDS-PAGE.
At -20°C for one year.
Induces stromal cells to produce proinflammatory and hematopoietic cytokines. Enhances the surface expression of the intracellular adhesion molecule-1 (ICAM-1) in fibroblasts.